Krebs Biochemicals & Industries (BOM:524518) LT-Debt-to-Total-Asset: 1.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524518 Krebs Biochemicals & Industries Ltd BOM:524518
40 GF Score
Price ₹57.25
GF Value ₹37.88
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Krebs Biochemicals & Industries LT-Debt-to-Total-Asset?

Krebs Biochemicals & Industries BOM:524518 +7.03% 40 LT-Debt-to-Total-Asset is 1.00 as of Mar. 2026. GuruFocus rates BOM:524518 with a GF Score™ of 40/100 and a GF Value™ of ₹37.88 (Significantly Overvalued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Krebs Biochemicals & Industries's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 1.00.

Krebs Biochemicals & Industries's long-term debt to total assets ratio declined from Mar. 2025 (1.22) to Mar. 2026 (1.00). It may suggest that Krebs Biochemicals & Industries is progressively becoming less dependent on debt to grow their business.

Krebs Biochemicals & Industries  (BOM:524518) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Krebs Biochemicals & Industries LT-Debt-to-Total-Asset Related Terms

Krebs Biochemicals & Industries LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Krebs Biochemicals & Industries's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Krebs Biochemicals & Industries LT-Debt-to-Total-Asset Chart

Krebs Biochemicals & Industries Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.94 1.25 1.28 1.22 1.00

Krebs Biochemicals & Industries Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.22 0.00 0.98 0.99 1.00
BOM:524518
40GF Score
Krebs Biochemicals & Industries Ltd BOM:524518
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Krebs Biochemicals & Industries LT-Debt-to-Total-Asset Calculation

Krebs Biochemicals & Industries's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (A: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 )/Total Assets (A: Mar. 2026 )
=1635.5/1632.467
=1.00

Krebs Biochemicals & Industries's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=1635.5/1632.467
=1.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 1.00 mean?
Krebs Biochemicals & Industries (BOM:524518) has a LT-Debt-to-Total-Asset of 1.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Krebs Biochemicals & Industries and its competitors.
Is Krebs Biochemicals & Industries' LT-Debt-to-Total-Asset too high?
Krebs Biochemicals & Industries' current LT-Debt-to-Total-Asset is 1.00. Overall, Krebs Biochemicals & Industries has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krebs Biochemicals & Industries' LT-Debt-to-Total-Asset compare to ZTS?
Krebs Biochemicals & Industries' LT-Debt-to-Total-Asset of 1.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Krebs Biochemicals & Industries and its competitors. Krebs Biochemicals & Industries's current LT-Debt-to-Total-Asset is 1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krebs Biochemicals & Industries stock overvalued right now?
Based on GuruFocus' analysis, Krebs Biochemicals & Industries (BOM:524518) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹37.88, compared to a current price of ₹57.25 — trading 51.1% above its estimated fair value. The current LT-Debt-to-Total-Asset is 1.00. Krebs Biochemicals & Industries' overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Krebs Biochemicals & Industries (BOM:524518), the current LT-Debt-to-Total-Asset is 1.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Krebs Biochemicals & Industries (BOM:524518) Overvalued in 2026?

Based on GuruFocus' analysis, Krebs Biochemicals & Industries stock appears to be overvalued. The current stock price of ₹57.25 is trading 51.1% above its estimated GF Value™ of ₹37.88. GuruFocus considers Krebs Biochemicals & Industries to be Significantly Overvalued.

Key valuation signals for BOM:524518:

  • LT-Debt-to-Total-Asset: 1.00
  • GF Value™: ₹37.88 vs. price of ₹57.25 (51.1% above fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the BOM:524518 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Krebs Biochemicals & Industries Business Description

Other Exchanges KREBSBIO:India
Address Kothapalli Village, Kasimkota Mandal, Anakapalli, Vishakapatnam, AP, IND, 531 031
Krebs Biochemicals & Industries Ltd is a biochemical company in India. It is engaged in the business of manufacture of active pharmaceutical ingredients. It has two manufacturing plants in Andhra Pradesh, India - one in Nellore and one in Vizag both Units are equipped for chemical synthesis, fermentation, and enzymatic technologies providing Krebs with production capacity.
40GF Score

Get the complete analysis for BOM:524518

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹57.25
Price
₹37.88
GF Value